ERS 2026 at a glance
Will respiratory treatment differentiation increasingly depend on biological segmentation, targeted mechanisms and digital innovation? From COPD and severe asthma to bronchiectasis, pulmonary fibrosis and pulmonary arterial hypertension (PAH), the congress is set to highlight emerging opportunities for more targeted treatment strategies and competitive differentiation.
📅 Build your schedule around the topics that matter most.
📥 Download the ERS 2026_Preview_by_LucidQuest
Key Respiratory Trends to Watch at ERS Congress 2026
COPD Treatment: IL-33, IL-5, TSLP and PDE3/4 Inhibition
IL-33, IL-5, TSLP/Type 2 inflammation and dual PDE3/4 inhibition could sharpen how treatment-responsive COPD populations are defined.
Severe Asthma: Biologics, Remission and Treatment Durability
TSLP/TSLPR, IL-5/IL-5R and multi-pathway approaches may increasingly compete on durability, remission and reduced treatment frequency.
Bronchiectasis: Brensocatib and Neutrophil-Targeted Therapies
Brensocatib and neutrophil biology will test whether inflammation-directed therapy can establish a treatment layer alongside infection-focused management.
Pulmonary Fibrosis: Nerandomilast, Treprostinil and Emerging Antifibrotics
Nerandomilast, inhaled treprostinil and emerging antifibrotics could increase the importance of matching mechanisms to disease phenotype, severity and stage.
Pulmonary Arterial Hypertension: Sotatercept, Ralinepag and Seralutinib
Sotatercept, ralinepag and seralutinib will keep earlier intervention, combination strategies and treatment sequencing firmly in focus.
Competitor and Industry Signals at ERS 2026
Tozorakimab: OBERON, TITANIA and FRONTIER-4 in COPD
OBERON, TITANIA and FRONTIER-4 will provide major clinical and mechanistic readouts for targeted inflammatory treatment in COPD.
BEAM-302: In Vivo Gene Editing for Alpha-1 Antitrypsin Deficiency
First-in-human Phase 1/2 data will provide an early clinical test of BEAM-302 and in vivo gene editing for severe alpha-1 antitrypsin deficiency (AATD).
Severe Asthma Pipeline: Verekitug, Lunsekimig, Tezepelumab and Depemokimab
Verekitug, lunsekimig, tezepelumab and depemokimab will test differentiation across pathway breadth, exacerbation control, durability and dosing frequency.
Artificial Intelligence and Machine Learning at ERS Congress 2026
DeepSpiro: Smartphone-Based Lung Function Assessment
DeepSpiro uses forced-exhalation sound for smartphone-based lung-function estimation. This approach could expand access to respiratory assessment if clinical utility extends beyond technical validation.
NodeAI and Imaging AI: Respiratory Diagnostics
Real-time endobronchial ultrasound (EBUS) support and AI-assisted lung imaging suggest digital tools are moving into defined diagnostic and disease-characterisation workflows.
What We Are Watching After ERS 2026
- Whether targeted COPD therapies generate sufficient evidence to support clearer biological segmentation and treatment selection.
- Whether emerging severe-asthma approaches demonstrate meaningful differentiation in durability, remission and dosing burden.
- Whether AI-enabled respiratory tools show enough clinical utility to influence routine assessment, earlier detection and treatment-response evaluation.
Download the ERS 2026 Preview Report
Download LucidQuest’s ERS Congress 2026 preview report for deeper analysis of emerging respiratory therapies, clinical developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the ERS 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
